Mostrando 5 resultados de: 5
Filtros aplicados
Publisher
Nature Structural and Molecular Biology(2)
EMBO Molecular Medicine(1)
Molecular Therapy - Nucleic Acids(1)
Theranostics(1)
Área temáticas
Enfermedades(3)
Microorganismos, hongos y algas(3)
Bioquímica(1)
Farmacología y terapéutica(1)
Medicina y salud(1)
Origen
scopus(5)
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 (Nature Structural & Molecular Biology, (2020), 27, 9, (846-854), 10.1038/s41594-020-0469-6)
OtherAbstract: In the version of this article initially published, author Jiandong Huo’s name was spelt incorrectlyPalabras claves:Autores:Bas A.L., Buttigieg K.R., Carrique L., Carroll M.W., Clare D.K., Coombes N., Dumoux M., Duyvesteyn H.M.E., Elmore M.J., Harrison P.J., Huo J., James W.S., Javier Gilbert Jaramillo, Knight M.L., Malinauskas T., Mikolajek H., Moynié L., Naismith J.H., Owens R.J., Radecke J., Ren J., Rijal P., Ruza R.R., Shah P.N.M., Stuart D.I., Tan T.K., Townsend A.R., Tree J.A., Vogirala V.K., Ward P.N., Weckener M., Zhao Y., Zhou D.Fuentes:scopusBroadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents
ArticleAbstract: Since its discovery, COVID-19 has rapidly spread across the globe and has had a massive toll on humaPalabras claves:aptamer, covid-19, modified DNA, MT: Oligonucleotides, SARS-COV-2, SELEX, Therapies and Applications, variants of concern, viral neutralizationAutores:Chadwick J., Chase C.N., Gelinas A.D., Harding A.C., James W.S., Janjic N., Javier Gilbert Jaramillo, Lee T., Liu S., Otis M.R., Ream B.E., Schneider D.J., Tan T.K., Zhang C.Fuentes:scopusG-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo
ArticleAbstract: Intronic GGGGCC repeat expansions in C9orf72 are the most common known cause of frontotemporal demenPalabras claves:amyotrophic lateral sclerosis, C9orf72, frontotemporal dementia, G-quadruplexAutores:Abdelkarim S., Balendra R., Boykin D.W., Calvo A., Chio A., Clarke M., Clayton E.L., Farahat A.A., Fratta P., Heslegrave A., Houlden H., Isaacs A.M., Ismail M.A., Javier Gilbert Jaramillo, Konrad M.T., Mitchell J.S., Moens T.G., Neidle S., Niccoli T., Nicoll A.J., Parkinson G., Partridge L., Patani R., Polke J.M., Preza E., Simone R., Stephens C.E., Vo T., Wilson K.M., Wilson W.D., Woodling N.S., Wray S., Zetterberg H.Fuentes:scopusNeutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
ArticleAbstract: The SARS-CoV-2 virus is more transmissible than previous coronaviruses and causes a more serious illPalabras claves:Autores:Buttigieg K.R., Carrique L., Carroll M.W., Clare D.K., Coombes N., Dumoux M., Duyvesteyn H.M.E., Elmore M.J., Harrison P.J., Huo J., James W.S., Javier Gilbert Jaramillo, Knight M.L., Le Bas A., Malinauskas T., Mikolajek H., Moynié L., Naismith J.H., Owens R.J., Radecke J., Ren J., Rijal P., Ruza R.R., Shah P.N.M., Stuart D.I., Tan T.K., Townsend A.R., Tree J.A., Vogirala V.K., Ward P.N., Weckener M., Zhao Y., Zhou D.Fuentes:scopusStructures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
ArticleAbstract: Background: Administration of potent anti-receptor-binding domain (RBD) monoclonal antibodies has bePalabras claves:Antibody cocktail, Antibody-antigen complex, Human monoclonal antibody, In vitro and in vivo function, Receptor-binding domain epitope, SARS-COV-2Autores:Buttigieg K.R., Carroll M.W., Charlton S., Chen C., Chen C.P., Chen X., Cheng S.H., Donat R.F., Duyvesteyn H.M.E., Fry E.E., Ginn H.M., Harding A.C., Huang K.Y.A., James W.S., Javier Gilbert Jaramillo, Lien C.E., Lin M.Y., Lin T.Y., Ma C., Qin L., Ren J., Rijal P., Schimanski L., Stuart D.I., Tan T.K., Townsend A.R., Tree J.A., Zhao Y., Zhou D.Fuentes:scopus